JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Journal of Endocrinology (1990) 125, 375-379       DOI: 10.1677/joe.0.1250375
© 1990 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bailey, C. J.
Right arrow Articles by Buchanan, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bailey, C. J.
Right arrow Articles by Buchanan, K. D.

Effects of gastric inhibitory polypeptide, vasoactive intestinal polypeptide and peptide histidine isoleucine on the secretion of hormones by isolated mouse pancreatic islets

 C. J. Bailey, L. C. Wilkes, J. M. Conlon, P. H. Armstrong and K. D. Buchanan

The release of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) by isolated mouse pancreatic islets was determined during 30-min incubations at 5.6 and 16.7 mmol glucose/l in the absence and presence of gastric inhibitory polypeptide (GIP), vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI) at concentrations of 1–1000 nmol/l. Insulin release was enhanced (>50%) by GIP (100–1000 nmol/l) and VIP (1 µmol/l) at 5.6 mmol glucose/l, but not at 16.7 mmol glucose/l. Glucagon release was increased by GIP (100–1000 nmol/l), and by VIP and PHI (1—1000 nmol/l) at both glucose concentrations in a dose-related manner (maximum increases > tenfold). Somatostatin release was similarly increased by GIP (10–1000 nmol/l) at both glucose concentrations. Only the highest concentration (1 µmol/l of PHI tested increased somatostatin release (twofold) at 5.6 mmol glucose/l, whereas PHI and VIP (1–1000 nmol/l reduced (>37%) somatostatin release at 16.7 mmol glucose/l. PP release was increased (49–58%) by 100–1000 nmol GIP/l, but was not significantly altered by VIP, and was reduced (39–56%) by PHI. The results indicate that GIP, VIP and PHI each stimulate glucagon release in a dose-related manner, but they exert discretely different effects on other islet hormones depending upon the dose and the prevailing glucose concentration.

Journal of Endocrinology (1990) 125, 375–379




This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. R Flatt, C. Day, and C. J Bailey
Review: Bariatric surgery: to treat diabesity
The British Journal of Diabetes & Vascular Disease, May 1, 2009; 9(3): 103 - 107.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. K. Olszewski, M. M. Wirth, T. J. Shaw, M. K. Grace, and A. S. Levine
Peptides that Regulate Food Intake: Effect of peptide histidine isoleucine on consummatory behavior in rats
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1445 - R1453.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. L.-Y. Tse, R. T.-K. Pang, A. O.-L. Wong, S.-M. Chan, H. Vaudry, and B. K.-C. Chow
Identification of a Potential Receptor for Both Peptide Histidine Isoleucine and Peptide Histidine Valine
Endocrinology, April 1, 2002; 143(4): 1327 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. F. Deacon, P. Danielsen, L. Klarskov, M. Olesen, and J. J. Holst
Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs
Diabetes, July 1, 2001; 50(7): 1588 - 1597.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the Society for Endocrinology.